Vardenafil (Levitra/Staxyn) vs Alprostadil (Caverject/MUSE): Long-Term Durability of Response

How Each Drug Works and Why Mechanism Matters for Long-Term Use

Vardenafil is a phosphodiesterase type-5 (PDE5) inhibitor. It blocks the enzyme that degrades cyclic GMP, the messenger that relaxes smooth muscle in the corpus cavernosum and allows blood to pool into an erection. Because this pathway depends on nitric oxide released by sexual stimulation, vardenafil produces an erection only when arousal is present. That design aligns with natural sexual spontaneity and is a major reason men continue using it long-term.

Alprostadil works through a different cascade entirely. It is a synthetic prostaglandin E1 (PGE1) analogue that directly binds EP2 and EP3 receptors on cavernosal smooth muscle cells, raising intracellular cyclic AMP independent of nitric oxide or sexual stimulation. The result is a pharmacological erection that occurs with or without arousal. That feature is clinically important for men with severe nerve damage (post-radical prostatectomy, diabetic autonomic neuropathy) where the nitric oxide pathway is functionally absent.

Pharmacokinetic Differences

Vardenafil reaches peak plasma concentration in roughly 60 minutes with a half-life of 4 to 5 hours. Food (especially high-fat meals) can delay absorption, while the Staxyn orally dissolving tablet formulation produces faster absorption in the fasted state compared with the Levitra film-coated tablet, with comparable bioavailability overall [1].

Alprostadil's pharmacokinetics differ by route. Intracavernosal Caverject achieves local tissue concentrations within minutes; systemic absorption is minimal because PGE1 is rapidly metabolized (approximately 80%) on first pass through the lungs. MUSE relies on urethral absorption and transfer to cavernosal tissue, making it less predictable; bioavailability is lower and more variable than the injection form [2].

Why Mechanism Predicts Durability

Men who respond to vardenafil tend to stay on it because the pill format is familiar, the erection is stimulus-dependent (which feels more natural), and systemic side effects are usually limited to mild headache, flushing, or nasal congestion. Men on alprostadil face a steeper learning curve and higher rates of local pain, which directly drives dropout. Understanding this mechanistic difference helps predict which agent a given patient will continue using at 12 or 24 months.

Long-Term Efficacy Data for Vardenafil

The Porst 2003 Open-Label Extension

The most cited long-term vardenafil dataset comes from Porst et al. (Int J Impot Res, 2003), a 12-month open-label extension study in 1,672 men with ED across multiple etiologies [3]. At 12 months, 68% of men reported being satisfied with their sexual experience, and mean International Index of Erectile Function (IIEF) erectile function domain scores improved by 7.5 points from baseline. Dropout due to lack of efficacy was under 8%. Adverse event-related dropout was under 3%. This durability profile held across diabetic and post-prostatectomy subgroups, though absolute response rates were lower in those populations compared with psychogenic or mild vascular ED.

PDE5 Inhibitor Class Durability: Broader Context

A Cochrane systematic review covering PDE5 inhibitors in men with ED found that IIEF domain score improvements were maintained across 12-month trial periods, with no significant attrition in efficacy signals over time [4]. Tachyphylaxis (the need for dose escalation to achieve the same effect) has not been demonstrated in controlled studies with vardenafil at 10 mg or 20 mg. The FDA-approved label for Levitra allows flexible dosing between 5 mg and 20 mg, giving clinicians room to optimize without switching agents [1].

Real-World Adherence

Real-world persistence data from pharmacy claims consistently show that oral PDE5 inhibitors have 12-month continuation rates of approximately 55 to 75%, with vardenafil performing comparably to sildenafil and tadalafil after adjusting for prescribing patterns. Men who self-report success on first or second attempt are significantly more likely to refill past the 6-month mark [5].

Long-Term Efficacy Data for Alprostadil

Linet et al. NEJM 1996: The Foundational Trial

The landmark home-use trial for intracavernosal alprostadil was Linet and Ogrinc (NEJM, 1996), a randomized, double-blind, placebo-controlled study in 296 men with ED [6]. In the active treatment arm, 87% of injection attempts resulted in intercourse, compared with 17% with placebo. At-home success was maintained across 18 months of the extension phase for men who continued. The authors noted, however, that only 58% of originally enrolled men completed the extension, underscoring the dropout problem even within a closely monitored research cohort.

Dropout Rates: The Central Durability Challenge

Alprostadil's efficacy when the drug is used is not seriously disputed. The problem is that fewer men keep using it. Published dropout analyses report 12-month discontinuation rates of 30 to 50% for intracavernosal alprostadil, with pain at the injection site (penile aching or burning) cited in 10 to 30% of cases and administration anxiety cited in another 10 to 20% [7]. Priapism (erection lasting more than 4 hours) occurs in approximately 1% of users and requires emergency intervention; penile fibrosis (corporal scarring from repeated injections) affects up to 5 to 12% of long-term users [2].

MUSE-Specific Durability

The MUSE (medicated urethral system for erection) formulation shows lower per-use efficacy than Caverject. Padma-Nathan et al. (1997) reported successful intercourse in 65% of at-home attempts with MUSE at doses of 125 to 1,000 mcg, versus 19% with placebo. Twelve-month continuation in that cohort was roughly 50%, limited by urethral burning (32% of users) and variable response [8]. MUSE is generally considered a second-tier alprostadil delivery option, used when injection is not acceptable.

Post-Prostatectomy Subgroup

Alprostadil has a specific durability advantage in post-radical prostatectomy patients who are PDE5 inhibitor non-responders. A prospective cohort of 100 men showed that intracavernosal alprostadil produced sufficient erections in 60 to 70% of nerve-sparing surgery patients who had failed sildenafil, and regular use was associated with a faster return of spontaneous erections, likely through penile rehabilitation mechanisms [9]. This is one scenario where alprostadil's long-term use is clinically preferred despite the higher dropout burden.

Head-to-Head Comparison: What the Data Show

No large randomized controlled trial has directly compared vardenafil to alprostadil in a head-to-head design powered for long-term durability as a primary endpoint. The comparison below synthesizes trial-level data across comparable populations.

Efficacy Per Attempt

| Endpoint | Vardenafil (Levitra 20 mg) | Alprostadil Caverject (20 mcg) | |---|---|---| | Successful intercourse per attempt | 65 to 75% | 70 to 87% | | Onset time | 30 to 60 min | 5 to 20 min | | Erection without arousal | No | Yes | | Duration of action | 4 to 5 hr window | 30 to 60 min erection |

Alprostadil produces a faster and in some trials a higher per-attempt success rate, particularly in severe vascular or neurogenic ED. Vardenafil's broader window of opportunity (up to 4 to 5 hours) may actually favor successful intercourse in real-world couple dynamics.

12-Month Continuation

| Agent | 12-month continuation (approximate) | |---|---| | Vardenafil (oral) | 65 to 80% | | Alprostadil injection (Caverject) | 50 to 70% (clinical trial); 40 to 55% (real-world) | | Alprostadil MUSE | 45 to 55% |

These figures reflect the pooled range across published studies. Vardenafil's oral route and lack of procedural burden give it a substantial adherence advantage in unselected ED populations.

Side Effect Profiles Affecting Long-Term Use

Vardenafil's most common adverse effects are headache (11 to 15%), flushing (10 to 11%), rhinitis (9%), and dyspepsia (4 to 5%). QTc prolongation risk means it should be avoided in men on class IA or III antiarrhythmics. Concurrent nitrate use is an absolute contraindication [1].

Alprostadil's side effects are local and procedural. Penile pain or aching occurs in 10 to 30% of Caverject users and up to 32% of MUSE users. Hypotension (systemic) is rare with injection but more common with MUSE because of urethral absorption. Prolonged erection requires urgent care. Long-term Caverject users should be monitored for fibrosis at the injection site every 3 to 6 months [2].

HealthRX Clinical Decision Framework: Vardenafil vs. Alprostadil

Use this framework as a starting point before a provider consultation:

Start with vardenafil if:

• ED is mild to moderate
• Nitric oxide pathway is at least partially intact (psychogenic, mild vascular, early diabetic)
• Patient prefers oral dosing
• Spontaneity and stimulus-dependent erection are acceptable

Move to or add alprostadil if:

• Two separate PDE5 inhibitors have failed at maximum tolerated dose
• ED is post-radical prostatectomy with incomplete nerve-sparing
• Severe arteriogenic or cavernosal venous leak has been documented
• Patient cannot use nitrate medications and vascular disease demands a non-systemic approach
• Penile rehabilitation protocol is prescribed by a urologist

Combination therapy (low-dose vardenafil plus low-dose alprostadil) is reserved for refractory ED under urologist supervision. Evidence for this combination exists but is limited to small prospective series [10].

Switching from Vardenafil to Alprostadil: When and How

Switching from vardenafil to alprostadil is appropriate when a trial of at least three to six attempts at the maximum tolerated vardenafil dose (20 mg with Levitra, or 10 mg with Staxyn due to bioequivalence differences) has failed to produce satisfactory erections. The American Urological Association (AUA) 2018 ED Guideline recommends offering intracavernosal injection therapy to PDE5 inhibitor non-responders as a second-line option [11].

Practical Steps for Switching

1. Document failure at maximum tolerated PDE5 inhibitor dose before transitioning.
2. Confirm no reversible causes (hypogonadism, uncontrolled diabetes, medication-induced ED) have been addressed.
3. Begin intracavernosal alprostadil at 2.5 mcg in-office for the first titration dose; titrate upward by 2.5 to 5 mcg increments at each visit until a 30-minute erection is achieved without excessive rigidity.
4. Train the patient and partner on injection technique before home use.
5. Instruct the patient to seek emergency care for any erection lasting over 4 hours.

Can Both Be Used Together?

Yes, but only under specialist guidance. Combination use is not FDA-approved as a fixed regimen, and the risk of prolonged erection increases. Some urologists prescribe a low-dose oral PDE5 inhibitor on days between alprostadil injections as part of penile rehabilitation, not concurrent with injection.

Special Populations: Where Each Drug Has a Durable Edge

Diabetic Men

Both agents work in diabetic ED, but absolute response rates are lower than in non-diabetic populations. Vardenafil 20 mg improved IIEF erectile function scores by 6.4 points (vs. 1.1 for placebo, P<0.001) in a trial of 452 diabetic men [12]. Alprostadil is effective even in diabetic men with autonomic neuropathy because it bypasses the nitric oxide cascade entirely; this makes it the preferred second-line agent when PDE5 inhibitors fail in diabetes.

Post-Prostatectomy Men

Vardenafil showed limited efficacy in the first 12 months after non-nerve-sparing prostatectomy. A randomized trial of vardenafil 10 mg nightly for 9 months post-prostatectomy showed IIEF scores no better than placebo at study end, though a modest benefit appeared in nerve-sparing subgroups [13]. Alprostadil injection, by contrast, produces erections regardless of nerve status and is the agent of choice in this population, often prescribed as part of a structured rehabilitation protocol beginning at 4 to 6 weeks post-surgery.

Cardiovascular Disease

Vardenafil is contraindicated with all nitrate formulations and requires caution in men with recent myocardial infarction (within 90 days), resting hypotension (systolic <90 mmHg), or severe heart failure. The Princeton Consensus III guidelines provide a sexual activity risk stratification framework for men with cardiovascular disease considering ED pharmacotherapy [14]. Alprostadil has negligible systemic hemodynamic effects when given via intracavernosal injection, making it safer from a cardiovascular standpoint in men who require concurrent nitrate therapy, though those patients still need cardiologist input on sexual activity readiness.

Patient and Partner Perspectives on Long-Term Satisfaction

Long-term satisfaction data from both partners matter. Rosen et al. (Urology, 2004) surveyed couples where the male partner used PDE5 inhibitors long-term; 71% of female partners reported improved relationship satisfaction after 12 months of consistent use [15]. Comparable partner-satisfaction data for alprostadil are thinner. The administration process for Caverject (visible injection immediately before sex) can disrupt spontaneity and create performance-related anxiety for both partners, which contributes to the real-world dropout burden beyond just the pain issue.

Men who succeed long-term with alprostadil typically develop a calm, practiced injection routine that reduces interruption. Support from a trained nurse or physician's assistant at injection initiation visits is associated with lower early dropout rates.

Cost and Accessibility Over Time

Cost affects long-term continuation. Generic vardenafil tablets (10 mg and 20 mg) became available in the United States after patent expiration and now cost approximately $1 to 6 per tablet through GoodRx discounts or telehealth platforms, compared with $40 to 80 per branded Levitra tablet. Generic alprostadil for injection (multiple manufacturers) costs approximately $8 to 25 per vial in the 10 to 40 mcg range; MUSE suppositories remain more expensive at $30 to 70 per unit.

The cost-per-successful-intercourse calculation favors generic vardenafil for most men in primary care ED settings, whereas alprostadil's higher per-unit cost is offset by its higher per-attempt success rate in refractory populations where vardenafil has already failed.